MAPK7 and benign prostatic hyperplasia: McCracken et al. observed a significant increase in ERK5 levels in prostate cancer compared to benign prostatic hyperplasia, with subsequent findings indicating that ERK5 elevates tumor cell proliferation, invasion, and migration [101].